



**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[www.gov.uk/mhra](http://www.gov.uk/mhra)

**11 January 2023**

Dear [REDACTED]

**FOI 22/1193**

Thank you for your enquiry dated the 13<sup>th</sup> of December where you requested Vaccine Analysis Prints (VAPs) for the below vaccines:

- Quadrivalent Influenza Vaccine, egg-grown (QIVe) manufactured by Sanofi Pasteur
- Influvac sub-unit Tetra, Quadrivalent Influenza Vaccine, egg-grown (QIVe) manufactured by Viartis (formerly Mylan)
- Cell-based Quadrivalent Influenza Vaccine (QIVc) manufactured by Seqirus
- Supemtek, recombinant Quadrivalent Influenza Vaccine (QIVr) manufactured by Sanofi Pasteur
- Adjuvanted Quadrivalent Influenza Vaccine (aQIV) manufactured by Seqirus

The MHRA continuously monitors the safety of medicines and vaccines through a variety of pharmacovigilance processes including the Yellow Card scheme. As part of our signal detection processes all adverse reaction reports received by the Yellow Card scheme are individually assessed and cumulative information reviewed at regular intervals. Any emerging evidence relating to possible risks associated with vaccines and medicines, is carefully reviewed and, if appropriate, regulatory action would be taken if any serious risks were confirmed.

Please find attached a Vaccine Analysis Print (VAP) for each requested vaccine which contains information on all UK spontaneous suspected ADR reports received through the Yellow Card scheme for that vaccine up to and including 13/12/2022. Please refer to the enclosed information sheet for guidelines on how to interpret the VAPs. Please be advised that due to the way medicines and vaccines are structured in our system we are unable to separate the two Seqirus manufactured vaccines (Cell-based Quadrivalent Influenza Vaccine (QIVc) & Adjuvanted Quadrivalent Influenza Vaccine (aQIV)) into individual VAPs. The combined VAP can be found attached as "Seqirus UK Quadrivalent Influenza Vaccine VAP".

As these data do not necessarily refer to proven side effects, you should refer to the product information which can be found here: [MHRA Products | Home](#) for details on the possible side effects of the vaccines.



When considering the provided spontaneous Adverse Drug Reaction (ADR) data, it is important to be aware of the following points:

- A reported reaction does not necessarily mean it has been caused by the vaccine, only that the reporter had a suspicion it may have. Each year, millions of doses of routine vaccines are given in the UK alone, and when any vaccine is administered to very large numbers of people, some recipients will inevitably experience illness following vaccination. The fact that symptoms occur after use of a vaccine, and are reported via the Yellow Card scheme, does not in itself mean that they are proven to have been caused by the vaccine. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.
- It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular drug, and may be stimulated by promotion and publicity about a drug. Reporting tends to be highest for newly introduced medicines during the first one to two years on the market and then falls over time. For these reasons the enclosed data should not be used as a basis for determining incidence of side effects.

I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team,

Vigilance and Risk Management of Medicines Division

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit

<https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF

Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.